Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Datadog Inc (DDOG) vs Cassava Sciences Inc (FLNA) Price & Performance

Datadog IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Datadog Inc vs Cassava Sciences Inc — how do they compare? Datadog Inc trades at $263.64 (market cap $96.37B), while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Datadog Inc is far larger — about 1830× Cassava Sciences Inc's market cap, and Datadog Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

DDOGFLNA
Market Cap
$96.37B$52.66M
Sector
TechnologyHealth
52-Week High
$277.49$4.64
52-Week Low
$102.62$1.09
Enterprise Value
$92.90B-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Datadog Inc

Datadog (DDOG) trades at $260.24, up 1.05% on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.58. Revenue growth remains robust, climbing from $1.7B in 2022 to $3.4B in 2025, though net income margin is modest at 3.69%. The company's acquisition of Adaptive ML aims to bolster its AI capabilities, positioning it for sustained growth in cloud observability.

The outlook for DDOG is positive, driven by solid revenue expansion and strategic AI investments, but high valuation multiples (P/E of 667.28, P/S of 25.79) pose risks if growth slows. Investor sentiment is overwhelmingly bullish, with 83% of analysts rating it a buy, though competition and market volatility require monitoring. The stock's momentum and institutional backing suggest further upside, contingent on continued execution and market conditions.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

Read more on DDOG

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA